SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co.
MTC 2.8200.0%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (1340)2/24/1999 12:27:00 AM
From: John R. Sashko  Read Replies (1) of 2539
 
Anthony,
Great article. It isn't more expensive. You know I had to complete 2 forms to switch a patient from Relafen to Celebrex. What bothers me is that the insurance company was actually saving money with the switch! Crazy world... I believe the so called experts are too worried about labeling. Most physicians are intelligent and will use a medication for off-label use as long as they believe it will benefit the patient. Convincing health plans to add Celebrex to their formulary should be the priority here.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News